AA amyloid nephropathy with predominant vascular deposition in Crohn's disease

Clinical Nephrology

Volumn 79, Issue 3, 2013, Pages 229-232

  Kurita, Noriaki ^a   Kotera, Nagaaki ^a   Ishimoto, Yu ^a   Tanaka, Mototsugu ^a   Tanaka, Shinji ^a   Toda, Nobuo ^b   Fujii, Akiko ^c   Kobayashi, Kiyonori ^d   Sugimoto, Tokuichiro ^a   Mise, Naobumi ^a  

^a Division of Nephrology   (Japan)

^b Kawasaki Medical School   (Japan)

^c MITSUI MEMORIAL HOSPITAL   (Japan)

^d KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

AA amyloidosis; Crohn's disease; Tubulointerstitial nephritis

Indexed keywords

AMYLOID A PROTEIN; AZATHIOPRINE; BETA 2 MICROGLOBULIN; CONGO RED; CREATININE; INFLIXIMAB; MESALAZINE; N ACETYL BETA GLUCOSAMINIDASE;

ADULT; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CASE REPORT; CELL INFILTRATION; CREATININE BLOOD LEVEL; CROHN DISEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FUNCTION; PROTEIN URINE LEVEL;

ADULT; AMYLOIDOSIS; CROHN DISEASE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; SERUM AMYLOID A PROTEIN;

EID: 84874969011     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107151     Document Type: Article

References (19)

1. Kane S. Urogenital complications of Crohn's disease. Am J Gastroenterol. 2006; 101 (Suppl): S640-S643. doi:10.1111/j.157 2-0241.2006 .0097 6. x PubMed
2. Greenstein AJ, Sachar DB, Panday AK, Dikman SH, Meyers S, Heimann T, Gumaste V, Werther JL, Janowitz HD. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992; 71: 261-270. doi:10.1097/00005792-199209000-00001 PubMed
3. Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr Nephrol. 2004; 19: 550-553. doi:10.1007/ s00467-004-1411-6 PubMed
4. Waters AM, Zachos M, Herzenberg AM, Harvey E, Rosenblum ND. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn's disease. Nat Clin Pract Nephrol. 2008; 4: 693-697. doi:10.1038/ncpneph0955 PubMed
5. Díaz Rodríguez C, Granja E, Vázquez Martul E, Sacristán F, Moreno Fernández A, González Rivero C, del Río Romero D, Trinidad JC. Association between membranous glomerulonephritis and Crohn's disease. Nefrologia. 2004; 24: 368-371. Spanish PubMed
6. Filiopoulos V, Trompouki S, Hadjiyannakos D, Paraskevakou H, Kamperoglou D, Vlassopoulos D. IgA nephropathy in association with Crohn's disease: a case report and brief review of the literature. Ren Fail. 2010; 32: 523-527. doi:10.31 09/08860221003710554 PubMed
7. Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int J Colorectal Dis. 2005; 20: 463-465. doi:10.1007/ s00384-004-0696-z PubMed
8. Gupta A, Pendyala P, Arora P, Sitrin MD. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab. J Clin Gastroenterol. 2011; 45: e30-e33. doi:10.1097/ MCG.0b013e3181fae913 PubMed
9. Koçak E, Köklü S, Akbal E, Huddam B, Azak A, Yilmaz SR. Development of glomerulonephritis early in the course of Crohn's disease. Inflamm Bowel Dis. 2010; 16: 548-549. PubMed
10. Leong J, Fung-Liu B. A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with Crohn's disease. Am J Gastroenterol. 2010; 105: 234-234. doi:10.1038/ajg.2009.500 PubMed
11. Presti ME, Neuschwander-Tetri BA, Vogler CA, Janney CG, Roche JK. Sclerosing cholangitis, inflammatory bowel disease, and glomerulonephritis: a case report of a rare triad. Dig Dis Sci. 1997; 42: 813-816. doi:10.1023/A:1018824416458 PubMed
12. Hopfer H, Wiech T, Mihatsch MJ. Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type. Nephrol Dial Transplant. 2011; 26: 2877-2884.
13. Uda H, Yokota A, Kobayashi K, Miyake T, Fushimi H, Maeda A, Saiki O. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006; 33: 1482-1487. PubMed
14. Westermark P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 2005; 272: 5942-5949. doi:10.1111/j.174 2-4658.2005.05 02 4.x PubMed
15. Brys R, Ringoir S, Elewaut A, Barbier F. Amyloidosis in Crohn's disease. Tijdschr Gastroenterol. 1972; 15: 322-327. Dutch PubMed
16. Iizuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut. 2006; 55: 744-745. doi:10.1136/gut.200 5.087577 PubMed
17. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis. 2008; 14: 431-432. doi:10 . 1002/ibd.20289 PubMed
18. Boscá MM, Pérez-Baylach CM, Solis MA, Antón R, Mayordomo E, Pons S, Mínguez M, Benages A. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut. 2006; 55: 294-295. doi:10.1136/gut.2005.082057 PubMed
19. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996; 11: 614-621. PubMed